IL-10M Fusion Protein Platform

Bi/Tri-TCE Platform

Antibody platform

IL-10M Fusion Protein Platform

FILTEN: Overcoming IL-10 limitations to enable broad applications in cancer and autoimmune diseases

- Overcome the limitations of short half-life and hematotoxicity of WT IL-10
- Bifunctional molecules exhibit superior efficacy
- Broad applications for oncology and autoimmune disease treatments

Bi/Tri-TCE Platform

TCE Platform: Combining high-performance core parts with unique structural design

Nanobody advantages:

● TCR/CD3 nanobody with cross-reactivity in primates;

● Co-stimulatory (second signal) nanobodies with adaptable activation profiles;

● Providing versatile solutions for complex molecular design requirements;

Strategy pipeline :

Prioritizing the development of 3rd generation TCEs, CD8 T cell-biased TCEs, and resistance-overcoming TCE variants to address resistance/relapse mechanisms.

Empowering multiple development strategies:

Engineered core sequences with tailored bioactivity support both in-house pipelines & external partnership.

Antibody platform